Developed by US medical company HistoSonics, the HistoSonics Histotripsy System generates microbubbles that rapidly expand and collapse, producing shock waves that break down tumours at the cellular level.
The Li Ka Shing Foundation (LKSF) and Temasek Trust (TT) have committed $12 million to bring innovative non-invasive ultrasound-based histotripsy tumour clinical trials to Singapore by purchasing and donating two Histotripsy Systems.
The National Cancer Centre Singapore (NCCS) and the National University Cancer Institute, Singapore (NCIS) will each receive one Histotripsy System — the first of such to be available in Southeast Asia.
